Literature DB >> 21788009

Transfusion increases the risk for vasoplegia after cardiac operations.

Andrej Alfirevic1, Meng Xu, Douglas Johnston, Priscilla Figueroa, Colleen G Koch.   

Abstract

BACKGROUND: Perioperative vasoplegia is associated with increased morbidity. Red blood cell (RBC) transfusion increases plasma concentrations of inflammatory mediators, possibly contributing to the development of vasoplegia. We investigated the prevalence of mild and profound postoperative vasoplegia, identified factors associated with its development, and examined the role of RBC and component transfusion on the occurrence of postoperative vasoplegia.
METHODS: Between January 1, 2000, and January 1, 2007, 25,960 patients underwent on-bypass cardiac surgical procedures. The incidence of vasoplegia was defined as (1) mild vasoplegia requiring norepinephrine infusion for blood pressure support on the day of operation and postoperative day 1, and (2) profound vasoplegia requiring vasopressin, with or without concomitant norepinephrine infusion, on the day of operation and postoperative day 1. Separate logistic regression models were used to model risk factors for development of mild and profound vasoplegia.
RESULTS: RBC transfusion increased risk-adjusted odd ratios (ORs) of developing mild vasoplegia (1.07 [95% confidence limits (CL), 1.05, 1.10]; p<0.001) and profound vasoplegia (1.38 [1.31, 1.46] p<0.001). The risk-adjusted ORs (95% CL) for mild vasoplegia and profound vasoplegia were similarly increased by fresh-frozen plasma (OR, 1.24 [1.10, 1.41], p<0.001; and OR, 1.20 [1.13, 1.29], p<0.001) and platelet transfusion (OR, 1.39 [1.25, 1.54], p<0.001; and OR, 1.22 [1.14, 1.31], p<0.001), respectively.
CONCLUSIONS: Red blood cells, fresh-frozen plasma, and platelet transfusion increased the prevalence of vasoplegia. RBC transfusion exhibited a dose-dependent response for developing vasoplegia with each RBC unit transfused. Further investigation is necessary to determine whether prophylactic use of vasopressor support in the setting of transfusion can ameliorate risk and effect outcomes.
Copyright © 2011 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21788009     DOI: 10.1016/j.athoracsur.2011.04.020

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  eComment. platelet transfusion after aortic valve replacement by the Freedom Solo bioprosthesis.

Authors:  Jamil Hajj-Chahine
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-04

2.  Risk assessment and outcomes of vasoplegia after cardiac surgery.

Authors:  Athanasios Tsiouris; Lynn Wilson; Ala S Haddadin; James J Yun; Abeel A Mangi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-06-13

3.  Methylene Blue for Vasoplegic Syndrome After Cardiac Operation: Early Administration Improves Survival.

Authors:  J Hunter Mehaffey; Lily E Johnston; Robert B Hawkins; Eric J Charles; Leora Yarboro; John A Kern; Gorav Ailawadi; Irving L Kron; Ravi K Ghanta
Journal:  Ann Thorac Surg       Date:  2017-05-24       Impact factor: 4.330

4.  Application of a TEG-Platelet Mapping Algorithm to Guide Reversal of Antiplatelet Agents in Adults with Mild-to-Moderate Traumatic Brain Injury: An Observational Pilot Study.

Authors:  Svetlana Kvint; Alexis Gutierrez; Anya Venezia; Eileen Maloney; James Schuster; Monisha A Kumar
Journal:  Neurocrit Care       Date:  2022-06-16       Impact factor: 3.210

5.  Cardiopulmonary bypass increases the risk of vasoplegic syndrome after coronary artery bypass grafting in patients with dialysis-dependent chronic renal failure.

Authors:  Nelson Américo Hossne Junior; Matheus Miranda; Marcus Rodrigo Monteiro; João Nelson Rodrigues Branco; Guilherme Flora Vargas; José Osmar Medina de Abreu Pestana; Walter José Gomes
Journal:  Rev Bras Cir Cardiovasc       Date:  2015 Jul-Aug

6.  Vasoplegia after implantation of a continuous flow left ventricular assist device: incidence, outcomes and predictors.

Authors:  Eric E C de Waal; Bas van Zaane; Marnix M van der Schoot; Albert Huisman; Faiz Ramjankhan; Wilton A van Klei; Nandor Marczin
Journal:  BMC Anesthesiol       Date:  2018-12-08       Impact factor: 2.217

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.